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Uranyl Photocleavage of Phosphopeptides Yields
Truncated C-Terminally Amidated Peptide Products
Rasmus L. B. Elnegaard,[a] Niels Erik Møllegaard,[b] Qiang Zhang,[b] Frank Kjeldsen,*[a] and
Thomas J. D. Jørgensen*[a]
Introduction
Every third protein is associated with metal ions, and in the
case of enzymes the metal ions are often found in the active
site where they serve an essential role for the enzymatically
catalysed chemical reaction.[1] The ability of metalloproteins to
coordinate specific metal ions has been exploited to engineer
a super uranyl-binding protein that binds uranyl (UO2
2+) with
extremely high affinity and selectivity.[2] This protein enables
the possibility to sequester uranyl directly from, for example,
sea water, where the uranyl concentration is 3 mg ton@1, thus
representing a possible source of uranium.[3] Uranyl is the most
stable and common ionic form of uranium in the aerobic envi-
ronment. Several recent studies have characterised the interac-
tions between uranyl and targeted proteins in vivo[4] and pep-
tide ligands.[5] The preferred uranyl-binding sites in proteins
and peptides consists predominantly of hard oxygen donors
such as carboxylate, phenolate and phosphate groups.[6]
Uranyl has excellent photocatalytic properties, as its excited
state is strongly oxidising.[7] Uranyl photocleavage has been
used for nearly three decades to investigate the conformation
of DNA and RNA structures and their interactions.[8] More re-
cently, uranyl has been used to photocleave the polypeptide
backbone in a number of uranyl-binding proteins.[9] Interest-
ingly, the photocleavage reaction is highly efficient, particularly
for phosphorylated uranyl-binding proteins, with backbone
cleavage occurring in the vicinity of the phosphorylated resi-
dues.[9b] This unique property has been exploited to use uranyl
as a two-pronged tool in a one-pot procedure, for purification
of C-terminally tagged recombinant proteins and photolytic
tag removal.[10] In this approach, the targeted protein is ex-
pressed with a C-terminal tag that is readily phosphorylated by
a kinase. By virtue of the high affinity of uranyl towards the
phosphorylated tag, the tagged protein is efficiently enriched
by immobilised uranyl. Subsequently, the tag is removed
through uranyl-induced photocleavage by irradiation with UV
light. Although uranyl has been demonstrated to function as
an artificial photochemical “protease”, the peptide products re-
sulting from uranyl photocleavage of proteins and peptides (as
well as the mechanism) have not been elucidated. It has been
suggested that uranyl photocleavage of a tetraphosphorylated
peptide obtained from b-casein yields peptide products with
a free C terminus (i.e. -COOH, similar to cleavage by proteolytic
enzymes).[9b] However, in this study we show that the peptide
products resulting from uranyl photocleavage of the b-casein
peptide do not have free C termini ; instead the photocleavage
products are C-terminally amidated (i.e. -CONH2). We arrive at
this conclusion after high-accuracy MS and MS/MS measure-
ments as well as enzymatic assays.
Our findings are potentially very interesting from a pharma-
ceutical perspective, as more than 50% of all biologically
active peptides in humans are amidated at the C terminus, and
this amidation is often directly linked to bioactivity.[11] Conse-
quently, there is great interest in the pharmaceutical industry
for cost-effective ways of generating C-terminally amidated
peptides. Accordingly, in 2007 amide formation was voted one
of the top challenges in green pharmaceutical chemistry by
the American Chemical Society.[12] Currently, most amidated
peptides are made by either standard chemical synthesis or
enzyme-catalysed reactions. The benefit of the enzymatic ap-
proach is that it avoids the relatively harsh chemicals, solvents
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and waste associated with traditional chemical synthesis.[12]
However, the enzymatic approach is limited by the substrate
specificity of the amidating enzyme, primarily peptidyl-glycine
a-amidating monoxygenase (PAM), which catalyses amidation
of peptides containing a C-terminal glycine.[13] In fact, amida-
tion of a series of pharmaceutically important peptides is
highly inefficient if not impossible by PAM.[13] Hence, increased
knowledge of uranyl-catalysed photocleavage might pave a
new way to efficiently generate C-terminally amidated pep-
tides.
Results and Discussion
Uranyl-induced photocleavage occurs with surprisingly high ef-
ficiency for a number of phosphorylated uranyl-binding pro-
teins.[9b] For example, uranyl-bound b-casein is quantitatively
cleaved into a few specific peptides upon UV irradiation. Simi-
larly, uranyl efficiently photocleaves the tetraphosphorylated
tryptic peptide derived from b-casein (residues 1–25: RELE-
ELNVPGEIVE(pS)L(pS)(pS)(pS)EESITR).[9b] Here we show that the
main products formed by uranyl photocleavage are C-terminal-
ly amidated peptides.
Briefly, b-casein peptide solution was mixed with a fivefold
molar excess of uranyl, as this ratio has previously been shown
to be optimal for the photocleavage reaction,[9b] and incubated
for 1 h at room temperature. The coordination of uranyl to the
b-casein peptide was confirmed by MS (Figure S1 in the Sup-
porting Information). The samples were placed on ice and irra-
diated with UV light (l=365 nm) for 15 min in solution. The
peptides were purified and desalted on reversed-phase micro
columns (this step also removes uranyl) followed by MS or MS/
MS analysis. Figure 1A shows the control MALDI TOF mass
spectrum of the intact b-casein peptide before UV irradiation.
The peak at m/z 3122.2 corresponds to the singly protonated
b-casein peptide (theoretical mass [M+H]+ 3122.2 Da), with
four peaks arising from sequential neutral losses of 98 Da
(H3PO4) from the phosphorylated serine residues. This neutral
loss is a well-known gas phase reaction that occurs in the
MALDI process.[14] The peak at m/z 1672.9 (“Int. Std.”) corre-
sponds to singly protonated neurotensin, which was added as
an internal mass calibrant.
Figure 1B shows the mass spectrum of the peptide products
formed by UV irradiation of uranyl-bound b-casein peptide.
Uranyl-induced photocleavage gives rise to three products: m/
z 1097.6 (peptide (1–9)), 1624.8 (1–14) and 1904.9, (1–16). Two
of the three cleavage sites are close to the phosphorylation
motifs at amino acid residues 15 and 17, as expected. The last
cleavage product might be a result of intramolecular folding of
the peptide in solution, but this is speculative as the specificity
of this photocleavage reaction is not fully understood. Interest-
ingly, the observed masses do not correspond to the theoreti-
cal masses of products formed by peptide bond hydrolysis.
The expected fragments generated by hydrolysis would be m/
z 1098.6, 1625.8 and 1905.9. These theoretical masses are 1 Da
higher, thus suggesting that the photocleavage reaction does
not results in peptide products with a free C-terminal -COOH.
Rather, the observed masses strongly suggest that the pep-
tides formed by uranyl photocleavage are C-terminally amidat-
ed (-CONH2). In order to obtain their masses with high accura-
cy, they were analysed with an ESI hybrid ion trap Orbitrap
mass spectrometer (Table 1). The masses of the truncated pep-
Figure 1. Mass spectra of the tetraphosphorylated b-casein peptide in the
presence of uranyl, A) without UV and B) after UV irradiation. Asterisked
peaks are MALDI-induced neutral losses of H3PO4 from the intact peptide.
C) Detail of mass spectra displaying the isotope distributions of the three
major photocleavage products. D) Sequence of the tetraphosphorylated b-
casein peptide. The observed cleavages are indicated with solid lines, with
residue number (above) and mass (below). Int. Std.= internal standard (neu-
rotensin).
Table 1. Comparison between theoretical and observed masses of the
photocleavage products. Theoretical masses were calculated in GPMAW
(www.gpmaw.com).
Fragment Theoretical mass [M+H]+ Observed mass
[M+H]+
Deviation: a-
amidation
Hydrolysis
(free
C-term.)
a-amidation
(C-term.
amidation)
MALDI-
TOF
Orbitrap vs. orbitrap
mass
1–9 1098.5790 1097.5950 1097.63 1097.5961 1.0 ppm
1–14 1625.8381 1624.8541 1624.82 1624.8565 1.5 ppm
1–16 1905.9205 1904.9365 1904.90 1904.9393 1.5 ppm
1–25 – – 3122.21 – –
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tides are in excellent agreement with the theoretical masses of
C-terminally amidated sequences (mass deviations <1.5 ppm).
To verify that their C termini are indeed amidated, the pep-
tides were subjected to collision induced dissociation (CID) ex-
periments. Figure 2A shows the CID spectrum for peptide (1–
9). The b8-fragment ion comprises the first eight residues (1–8),
and its mass agrees well with the unmodified sequence (mass
deviation 0.5 ppm). The mass of the C-terminal residue was
readily obtained by subtracting the mass of the b8-fragment
ion from the mass of the peptide ion (1–9) (i.e. precursor ion
mass). The experimental mass of the C-terminal proline residue
clearly shows that it was amidated, as proved by the excellent
agreement with the theoretical mass for an amidated proline
amino acid (mass deviation 1.9 ppm). Consequently, the CID
spectrum of peptide (1–9) confirms unambiguously that its
C terminus was amidated. Similarly, the CID spectrum of pep-
tide (1–14) (Figure 2B) demonstrates that residues 1–13 are un-
modified, as the mass of the b13-fragment ion fits well with the
theoretical mass of the unmodified sequence (mass deviation
1.3 ppm). The C-terminal residue is contained within the y6-
fragment ion of residues 9–14 (Figure 2B), and the mass of this
fragment ion is in excellent agreement with the theoretical
mass of the amidated sequence (mass deviation 1.2 ppm). The
masses of the two fragment ions (b13
2+ and y6
+) thus provide
conclusive evidence for the amidation of C terminus in peptide
(1–14). The CID product spectrum of peptide (1–16) contains
a rich set of b- and y-fragment ions (Figure 2C). Again, all b-
fragment ions corresponded to unmodified sequences, where-
as the masses of the y-fragment ions corresponded to sequen-
ces with an amidated C-terminal Leu residue (y4
+ , mass devia-
tion 0.6 ppm). It should be noted that the absence of b14- and
b15-fragment ions means that the amidation is localised to the
last three residues of peptide (1–16), that is, -Glu-pSer-Leu.
However, as the amidation was located at the C terminus in
peptide (1–9) and peptide (1–14), we consider it is most likely
that this is also the case for peptide (1–16).
To further validate the presence of an amidated C terminus
in the peptide products of uranyl photocleavage, we incubated
the photocleaved sample with an exopeptidase (carboxypepti-
dase Y) that enzymatically cleaves peptides from their C-termi-
nal ends, but requires a free C terminus (-COOH) for full enzy-
matic activity.[15] An amidated C terminus will thus protect a
peptide from enzymatic degradation. When the photocleaved
sample was incubated with carboxypeptidase Y, there was no
sign of degradation of any of the peptides formed by uranyl
photocleavage. However, the peak corresponding to the inter-
nal standard (neurotensin) disappeared, and several peaks cor-
responding to partial degradation products of the internal
standard appeared (Figure S2). Together with the CID data, this
orthogonal enzymatic assay provides strong evidence that
peptides (1–9), (1–14) and (1–16) formed by uranyl photocleav-
age are C-terminally amidated. Our results highlight the impor-
tance of using high-accuracy mass spectrometers for unambig-
uous characterisation of peptides.
In order to confirm the requirement of uranyl for the photo-
cleavage reaction, the b-casein peptide was UV irradiated in
the absence of uranyl. As expected, no photocleavage was ob-
served without uranyl (Figure S3). In addition, the importance
of the phosphate groups in the b-casein peptide was investi-
gated. A peptide with the same sequence but without phos-
phorylation (RELEELNVPGEIVESLSSSEESITR) was UV irradiated in
the presence of uranyl. No photocleavage was observed, thus
testifying that phosphate groups are required for the cleavage
Figure 2. CID spectra of peptides (1–9), (1–14) and (1–16) formed by uranyl
photocleavage of the b-casein peptide. Mass spectra of photocleavage prod-
ucts with precursor masses: A) m/z 549.30, 2+ (1097.6 Da), B) m/z 812.93,
2+ (1624.9 Da), and C) m/z 953.47, 2+ (1904.9 Da). Sequences of the respec-
tive photocleavage products are shown below each spectrum, indicating
the identified b- and y-ions.
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reaction, most likely because they present efficient uranyl-bind-
ing sites in the peptide (Figure S4).
The discovery that the photolytic cleavage yields C-terminal-
ly amidated peptides suggests that the backbone cleavage
mechanism could follow an a-amidation-like pathway
(Scheme 1A).[16] This pathway requires oxygen (Scheme 1).
In order to investigate whether the uranyl photocleavage re-
action exhibits a similar dependence on oxygen, we conducted
the experiment under essentially oxygen-free conditions.
Oxygen was efficiently removed by bubbling xenon gas
through the solution in a glovebox containing an inert nitro-
gen atmosphere (Figure S5). Figure 3 shows the mass spectrum
obtained from UV irradiation of uranyl-bound b-casein peptide
in an oxygen-free environment. Interestingly, in the absence of
oxygen there was no formation of photocleavage products
(Figure 3B). In contrast, uranyl photocleavage of DNA has been
reported to occur also under oxygen-free conditions.[18] The
strong oxygen dependence of uranyl-induced photocleavage
thus appears to be unique for polypeptide backbone cleavage.
There are several lines of evidence to support the involve-
ment of a radical-mediated mechanism, akin to the a-amida-
tion pathway (Scheme 1A) for polypeptide backbone cleavage
by UV-activated uranyl. Firstly, uranyl is strongly oxidising in
the excited state, and it has been reported to efficiently photo-
oxidise organic compounds by hydrogen abstraction upon UV
irradiation.[7, 17a] Secondly, the first step for radical-mediated oxi-
dative cleavage of a polypeptide backbone (by, for example,
hydroxyl radical attack) is hydrogen abstraction from typically
the a-carbon, b-carbon (C-3) or g-(C-4) sites on the amino acid
side-chains.[16] In the following step, the a-carbon-centred radi-
cal reacts with molecular oxygen to give an intermediate
peroxy radical, which forms an imine species upon loss of
OOHC ; this in turn is readily hydrolysed to form a C-terminally
amidated peptide and a ketoacyl peptide (a-amidation path-
way; cleavage of the N@Ca bond; Scheme 1). It should be
noted that the peroxy radical can also follow the “diamide
Scheme 1. Proposed mechanism for uranyl-dependent photocleavage. The two suggested pathways are A) the a-amidation pathway and B) the diamide
pathway. R groups=amino acid side chains. Adapted from refs. [17a] and [17b].
Figure 3. Mass spectra obtained from the b-casein peptide incubated with
uranyl in an essentially oxygen-free environment, A) without UV and B) after
UV irradiation. Asterisked peaks are MALDI-induced neutral losses of H3PO4
from the intact peptide. The experiment was carried out in a glovebox
(oxygen <1 ppm). Prior to UV irradiation the samples were degassed by
bubbling xenon through the samples for 5 min. Finally the samples were de-
salted and the mass was analysed by MALDI-MS. Int. Std.= internal standard
(neurotensin).
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pathway” for backbone cleavage, where the Ca@CO bond is
cleaved to form an imide (N-terminal fragment) and a peptide
isocyanate (C-terminal fragment, which is further hydrolysed to
yield CO2 and a peptide; Scheme 1B). For hydroxyl radical-
mediated oxidative backbone cleavage, the products from
both pathways are typically observed.[16a] For example, metal-
catalysed oxidation of proteins or peptides typically leads to
products formed by both the a-amidation and diamide path-
ways.[19]
At first glance, the MALDI mass spectra suggest that uranyl
photocleavage proceeds solely by an a-amidation-like pathway
to yield exclusively C-terminally amidated peptides. However,
closer inspection of the MALDI spectrum (Figure 1) reveals
a minor peak at m/z 1125.6. We attribute this to the diamide
product formed by a similar a-carbon-centred radical, as that
leading to the a-amidation product (1–9) at m/z 1097.6. How-
ever, there are no other peaks in the MALDI spectrum corre-
sponding to diamide products (m/z 1762.8 and m/z 2042.8)
formed by a similar a-carbon-centred radical as that leading to
the a-amidation products (1–14) and (1–16). Thus, the reaction
studied here, as measured by MALDI MS, seems to favour the
a-amidation pathway over the diamide pathway.
The high preference of uranyl photocleavage to follow an
a-amidation-like pathway is highly important for its potential
to synthesise pharmaceutical relevant C-terminally amidated
peptides. Importantly, in contrast to metal-catalysed oxidation,
uranyl photo-oxidation seems to strongly favour backbone
cleavage over other types of oxidative modification (e.g. side-
chain oxidation, carbonylation, side-chain cleavage).[19,20] In
order to put this into perspective, bovine serum albumin was
found to undergo oxidative damage at 106 different residues
in in vitro metal-catalysed oxidation.[21] In this respect, uranyl
appears to present a novel approach to achieve site-selective
cleavage to yield C-terminally amidated peptides with limited
byproducts. In a pharmaceutical setting, purity of the final
product is a concern, as would be uranyl toxicity. The uranyl
salt is catalytic and is not incorporated into the photocleavage
products. However, proper immobilisation or chromatographic
purification of excess uranyl is of absolute importance in fur-
ther development.
Conclusion
By using high-accuracy mass spectrometry, collision-induced
dissociation experiments and an enzymatic assay, we have
unambiguously demonstrated that the peptides formed by
uranyl photocleavage are C-terminally amidated. The uranyl
photocleavage reaction depends on the presence of oxygen;
in the absence of oxygen, no cleavage products were ob-
served. We hypothesise that the photocleavage reaction pref-
erentially follows an a-amidation-like pathway. The efficient
cleavage suggests that uranyl photocleavage could be used as
an alternative way of producing pharmaceutically relevant C-
terminally amidated peptides. In this light, studying the mech-
anism and cleavage pattern of uranyl photocleavage in even
more detail holds great potential. Using the b-casein model
peptide, we observe three distinct photocleavage products,
which would require an additional chromatographic purifica-
tion step in a pharmaceutical setting. Thus, understanding
what determines the cleavage specificity is important and
should be addressed in future studies. This might give rise to
the identification of specific peptide sequences that result only
in one photocleavage product and therefore would be more
suitable for pharmaceutical production.
Experimental Section
Sample preparation: UO2(NO3)2 (catalogue no. 94270, Sigma–Al-
drich) was dissolved in ultrapure Milli-Q water at RT to give
a 100 mm stock solution. Concentrations above 1 mm favour the
nitrato complex UO2(NO3)2 in solution over hydrolysis of uranyl.
[22]
Immediately before use, the uranyl solution was diluted (500 mm)
in Tris·HCl (20 mm, pH 8.0). The reactions were carried out in low-
binding Eppendorf tubes containing synthetic b-casein peptide
(10 mm >95% purity; AnaSpec), UO2(NO3)2 (50 mm) and neuroten-
sin (0.5 mm; internal standard, >90% purity; Sigma–Aldrich) in
Tris·HCl (20 mm, pH 8.0). For the experiment with the nonphos-
phorylated peptide a synthetic nonphosphorylated b-casein pep-
tide was used (>93.8% purity; GenScript, Nanjing, China).
UV irradiation/photocleavage: Samples (20 mL) were transferred
to the lids of 1.5 mL low-binding Eppendorf tubes, and the lids
were placed on a freezer block (0 8C). The UV lamp (6 W; UVP,
Upland, CA) was placed 1.0 cm directly above the lids, then the
samples were irradiated (365 nm) for 15 min, transferred to low-
binding tubes and stored at @20 8C.
Experiments under oxygen-free conditions: All samples and
equipment were transferred through an airlock into a glovebox
with an oxygen concentration below 1 ppm. Samples were de-
gassed by bubbling xenon (Air Liquide Taastrup, Denmark) through
the solution for 5 min. Samples were transferred to lids from Ep-
pendorf tubes, and UV irradiation was performed in the glovebox
as described above.
Oxygraph measurements: The oxygen level was monitored with
an oxygraph+ (Hansatech Instruments, Kings Lynn, UK) to deter-
mine the time required to remove oxygen from Tris·HCL buffer.
Tris·HCl (500 mL, 20 mm, pH 8) was placed in the oxygraph cham-
ber with a stirring magnet in the bottom, and the chamber was
sealed. When a stable oxygen level was observed, xenon was bub-
bled continuously into the solution through the chamber inlet,
while observing the oxygen concentration until a stable reading of
zero oxygen was achieved.
Desalting: Samples were dried in a Concentrator Plus vacuum cen-
trifuge (Eppendorf) and redissolved in formic acid (0.1%). Samples
were desalted on reversed-phase microcolumns packed in stage
tips by using a C8 plug and Oligo R3 resin (Applied Biosystems).
The columns were equilibrated with formic acid (0.1%), and the
sample (also in 0.1% formic acid) was loaded. The column was
washed with formic acid (0.1%), and the sample was eluted using
acetonitrile/water (20 mL, 1:1 v/v) containing formic acid (0.1%).
Carboxypeptidase Y treatment: Samples were prepared as de-
scribed above (i.e. , 10 mm b-casein peptide, 50 mm UO2(NO3)2 and
0.5 mm neurotensin in Tris·HCl). The UV-irradiated samples (not de-
salted) were mixed with citrate buffer (18 mL, 0.1m, pH 6) and car-
boxypeptidase Y (2 mL, 5 UmL@1 in citrate buffer; Sigma–Aldrich),
and incubated over night at 25 8C. Samples were desalted before
MALDI-MS analysis.
ChemBioChem 2017, 18, 1117 – 1122 www.chembiochem.org T 2017 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim1121
Full Papers
MALDI-MS : The sample (0.5 mL) was spotted with matrix solution
(0.5 mL; acetonitrile (70%) in Milli-Q water with TFA (0.1%, v/v), sa-
turated with 2,5-dihydroxybenzoic acid) on the MALDI target and
left to air-dry. Samples were analysed with a 4800 MALDI-TOF/TOF
analyser (AB Sciex, Framingham, MA) in the reflector mode to en-
hance the mass resolution.
ESI-MS: Desalted samples dissolved in acetonitrile (50%) in Milli-Q
water with (v/v) formic acid (0.1%) were loaded into nanoES spray
capillaries (Thermo Fisher Scientific) and analysed by ESI-MS on an
LTQ Orbitrap Velos Pro (Thermo Fisher Scientific) in the positive-ion
mode with a resolution of 30000, m/z 200–2000 (capillary tempera-
ture: 270 8C; S-Lens RF level: 61.5%). CID fragmentation was per-
formed with normalised collisional energy at 30.
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